These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16183420)

  • 1. Trends in intravenous iron use among dialysis patients in the United States (1994-2002).
    St Peter WL; Obrador GT; Roberts TL; Collins AJ
    Am J Kidney Dis; 2005 Oct; 46(4):650-60. PubMed ID: 16183420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
    Winkelmayer WC; Goldstein BA; Mitani AA; Ding VY; Airy M; Mandayam S; Chang TI; Brookhart MA; Fishbane S
    Am J Kidney Dis; 2017 Jun; 69(6):771-779. PubMed ID: 28063734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous ferric saccharate as an iron supplement in dialysis patients.
    Silverberg DS; Blum M; Peer G; Kaplan E; Iaina A
    Nephron; 1996; 72(3):413-7. PubMed ID: 8852489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients.
    Airy M; Mandayam S; Mitani AA; Chang TI; Ding VY; Brookhart MA; Goldstein BA; Winkelmayer WC
    Nephrol Dial Transplant; 2015 Dec; 30(12):2068-75. PubMed ID: 26311216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parenteral iron use in the management of anemia in end-stage renal disease patients.
    Bailie GR; Johnson CA; Mason NA
    Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
    Warady BA; Zobrist RH; Wu J; Finan E;
    Pediatr Nephrol; 2005 Sep; 20(9):1320-7. PubMed ID: 15971073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
    Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
    Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
    Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
    JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
    Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
    Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
    Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration.
    Folkert VW; Michael B; Agarwal R; Coyne DW; Dahl N; Myirski P; Warnock DG;
    Am J Kidney Dis; 2003 Mar; 41(3):651-7. PubMed ID: 12612989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients.
    Solak Y; Atalay H; Guney I; Turkmen K; Kaya E; Turk S
    Ren Fail; 2011; 33(3):307-11. PubMed ID: 21401355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia.
    Li H; Wang SX
    Perit Dial Int; 2008; 28(2):149-54. PubMed ID: 18332450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
    Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
    J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.
    Barbieri C; Bolzoni E; Mari F; Cattinelli I; Bellocchio F; Martin JD; Amato C; Stopper A; Gatti E; Macdougall IC; Stuard S; Canaud B
    PLoS One; 2016; 11(3):e0148938. PubMed ID: 26939055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous iron therapy in chronic kidney disease and peritoneal dialysis patients.
    Folkert VW
    Nephrol Nurs J; 2003 Oct; 30(5):571-6, 584. PubMed ID: 14621635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.